Chronic Rhinosinusitis With Nasal Polyps Market Report 2026

The chronic rhinosinusitis with nasal polyps market size has grown strongly in recent years. It will grow from $4.38 billion in 2025 to $4.78 billion in 2026 at a compound annual growth rate (CAGR) of 9%. The growth in the historic period can be attributed to increasing prevalence of chronic sinus disorders, wider use of corticosteroid nasal sprays, growth in ENT specialist consultations, improved diagnostic imaging access, increased awareness of inflammatory sinus diseases.

The chronic rhinosinusitis with nasal polyps market size is expected to see strong growth in the next few years. It will grow to $6.5 billion in 2030 at a compound annual growth rate (CAGR) of 8%. The growth in the forecast period can be attributed to increasing approvals of monoclonal antibody therapies, rising investment in ENT biologics research, expansion of outpatient sinus surgery procedures, growing focus on recurrence prevention, increasing patient preference for non-surgical options. Major trends in the forecast period include increasing adoption of biologic therapies for crswnp, rising use of minimally invasive surgical techniques, growing focus on long-term inflammation control, expansion of personalized treatment pathways, enhanced integration of diagnostic imaging and biomarkers.

The rising prevalence of respiratory diseases is expected to drive the growth of the chronic rhinosinusitis with nasal polyps market in the coming years. Respiratory diseases include a wide range of conditions affecting the airways and lungs. The increasing incidence of these conditions is driven by a combination of factors such as air pollution, smoking, climate change, infections, occupational exposure, and allergies. As the number of people affected by conditions such as asthma and chronic obstructive pulmonary disease increases, the occurrence of related conditions such as chronic rhinosinusitis with nasal polyps also rises, leading to higher demand for diagnostic tools, treatments, and surgical interventions. For instance, in December 2023, according to the National Center for Biotechnology Information, a US-based government agency, the global prevalence of chronic obstructive pulmonary disease is projected to approach 600 million cases worldwide by 2050. Therefore, the growing prevalence of respiratory diseases is contributing to the growth of the chronic rhinosinusitis with nasal polyps market.

Major companies operating in the chronic rhinosinusitis with nasal polyps market are focusing on alternative treatment approaches, including anti-IL-5 biologics, to improve patient outcomes and strengthen their competitive position. Anti-IL-5 biologics provide targeted therapy by reducing eosinophilic inflammation in conditions such as severe asthma and other eosinophilic disorders, thereby improving symptom control and quality of life. For example, in March 2024, Optinose, a US-based pharmaceutical company focused on developing and commercializing innovative therapies, received approval from the US Food and Drug Administration for XHANCE, a prescription nasal spray indicated for the treatment of chronic rhinosinusitis in adults, including both chronic rhinosinusitis with nasal polyps and chronic rhinosinusitis without nasal polyps. XHANCE contains fluticasone propionate, a corticosteroid that helps reduce inflammation in the nasal passages. A key feature of the product is its Exhalation Delivery System, which enables patients to blow into the device during administration, improving drug delivery deep into the nasal passages and effectively targeting areas where nasal polyps develop and sinuses drain.

In May 2025, Paratek Pharmaceuticals, a US-based biopharmaceutical company specializing in antibacterial and anti-infective therapies, acquired Optinose Inc. for an undisclosed amount. This acquisition is intended to expand Paratek’s specialty therapeutics portfolio, enhance its commercial capabilities, and increase its presence in respiratory and ear, nose, and throat treatment segments. Optinose Inc. is a US-based specialty pharmaceutical company that provides therapies for chronic rhinosinusitis with nasal polyps.

Major companies operating in the chronic rhinosinusitis with nasal polyps market are Pfizer Inc., Roche Holding AG, Merck & Co Inc, Bayer AG, Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Medtronic plc, Boehringer Ingelheim International GmbH, Amgen Inc, Teva Pharmaceutical Industries Ltd, Regeneron Pharmaceuticals Inc, Daiichi Sankyo Company Limited, Olympus Corporation, Eisai Co Ltd, Smith & Nephew PLC, Genentech USA Inc, Mallinckrodt Pharmaceuticals, Lyra Therapeutics Inc, Sunovion Pharmaceuticals, Acclarent Inc., Optinose US Inc, SinuSys Corporation, Biohaven Pharmaceuticals.

North America was the largest region in the chronic rhinosinusitis with nasal polyps market in 2025. The regions covered in the chronic rhinosinusitis with nasal polyps market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the chronic rhinosinusitis with nasal polyps market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the chronic rhinosinusitis with nasal polyps market by increasing costs of imported biologic drugs, surgical instruments, diagnostic imaging equipment, and pharmaceutical ingredients. Europe and North America are most affected due to reliance on specialized biologics manufacturing, while Asia-Pacific faces pricing pressure on advanced ENT therapeutics. These tariffs are influencing treatment affordability and healthcare budgets. However, they are also encouraging domestic biologic production, regional clinical trials, and localized manufacturing of ENT medical devices and therapies.

The chronic rhinosinusitis with nasal polyps market research report is one of a series of new reports that provides chronic rhinosinusitis with nasal polyps market statistics, including chronic rhinosinusitis with nasal polyps industry global market size, regional shares, competitors with a chronic rhinosinusitis with nasal polyps market share, detailed chronic rhinosinusitis with nasal polyps market segments, market trends and opportunities, and any further data you may need to thrive in the chronic rhinosinusitis with nasal polyps industry. This chronic rhinosinusitis with nasal polyps market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Chronic rhinosinusitis with nasal polyps (CRSwNP) is a long-term inflammatory disorder affecting the sinuses and nasal passages, marked by the presence of nasal polyps. Nasal polyps are noncancerous, swollen tissue growths that develop in the nasal passages or sinuses as a result of prolonged inflammation. The condition is identified through a combination of symptom evaluation, clinical examination, imaging studies, allergy testing, and, in some cases, biopsy.

The primary treatment types for chronic rhinosinusitis with nasal polyps include medications and surgical approaches. Medications used for this condition are intended to reduce inflammation, control symptoms, and shrink nasal polyps. These treatments are administered through nasal, oral, and other routes, and are distributed via hospital pharmacies, retail pharmacies, and online pharmacies.

The chronic rhinosinusitis with nasal polyps market consists of revenues earned by entities by providing services such as medical consultations, diagnostic procedures, pharmacological treatments, and surgical interventions. The market value includes the value of related goods sold by the service provider or included within the service offering. The chronic rhinosinusitis with nasal polyps market also includes sales of nasal corticosteroid sprays, antihistamines, saline nasal sprays, and devices for nasal irrigation, as well as surgical instruments and equipment used in procedures like polypectomy and functional endoscopic sinus surgery. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.